Claims.

- Use of piperazine phenothiazine derivatives, or a pharma-1. ceutically acceptable salt orester thereof, in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on CNS and/or PNS.
- 2. Use according to claim 1 wherein the piperazine phenothiazine derivatives are selected from compounds of 10 formula I

$$\begin{array}{c|c}
S & R1 \\
R2 & R3 \\
N & R6 \\
R4 & R5
\end{array}$$
(I)

wherein

20

25

A represents a straight or branched alkylene chain of from 2 to 6 carbon atoms separating the nitrogen atoms linked thereto by at least two carbon atoms;

R1 represents hydrogen, halogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkyl-mercapto, trifluoromethylmercapto, lower alkyl-sulfonyl (preferably methylsulfonyl), perfluoroalkyl of 1 to 3 carbon atoms;

R2, R3, R4 and R5 each represent methyl, ethyl or hydrogen, R6 represents hydrogen, lower alkyl, hydroxy-lower-alkyl or aliphatic acyloxy-lower-alkyl having 1 to 4 carbon atoms in the acyloxy portion and 1 to 6 carbon atoms in the alkyl portion, CH_2-CH_2-O-R7 where R7 represents hydrogen, COR8 where

WO 2004/096231 PCT/EP2004/005183

15

R8 is a branched or straight chain alkyl radical of from seven to fourteen carbon atoms;

in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on CNS and/or PNS.

5

- 3. Use according to claim 2 wherein
- A represents ethylene, propylene or 2- methylpropylene;
- R1 represents hydrogen, chloro, COCH3, -CF3;
- R2, R3, R4 and R5 each represent hydrogen;
- R6 represents CH_3 , CH_2-CH_2-O-R7 where R7 represents hydrogen, COR8 where R8 is a straight chain alkyl radical of from seven to fourteen carbon atoms.
- 4. Use according to claims 1 to 3, wherein the piperazine phenothiazine derivatives is flufenazine, or a pharmaceutically acceptable salt or ester thereof, in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on CNS and/or PNS.
- 20 5. Use according to claims 1 to 4, in the manufacture of a medicament for the treatment of central and/or peripheral neurodegenerative diseases.
- Use according to claims 1 to 5, in the manufacture of a
 medicament for the treatment of Parkinson's disease.
 - 7. Use according to claims 1 to 5, in the manufacture of a medicament for the treatment of Alzheimer's disease.
- 30 8. Use according to claims 1 to 5, in the manufacture of a medicament for the treatment of peripheral neuropathy diseases.

WO 2004/096231 PCT/EP2004/005183

16

- 9. Use according to claim 8, in the manufacture of a medicament for the treatment of amyotrophic lateral sclerosis (ALS) diseases.
- 5 10. Use according to any one of claims 1 to 9, wherein the medicament is for oral, rectal, subcutaneous, intramuscular or intravascular administration route.
- 11. Use according to any one of claims 1 to 10, wherein the medicament comprises as active ingredient from 0,2mg to 500mg of the piperazine phenothiazine derivatives.
- 12. Use according to any one of claims 1 to 11, wherein the medicament is administrated at doses comprised between 0.1mg/kg to 10mg/kg.